导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.66% | 3291/4773 |
| 近一周 | -2.44% | 2178/5462 |
| 近一月 | -2.72% | 1375/5421 |
| 近一季 | -5.09% | 1765/5209 |
| 近半年 | -4.52% | 2538/4920 |
| 近一年 | -1.13% | 2836/4366 |
| 近两年 | 37.97% | 1976/2954 |
| 近三年 | 23.61% | 1338/2253 |
| 成立以来 | 83.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.59% 3881/4961 |
5.47% 2881/5312 |
- - |
- - |
| 2025 | 19.64% 2197/4813 |
-0.27% 2166/3635 |
2.48% 1544/4076 |
15.43% 2804/4524 |
1.42% 1384/4813 |
| 2024 | 15.79% 882/3463 |
4.88% 422/2808 |
-1.39% 1057/3014 |
14.89% 1883/3129 |
-2.55% 2128/3463 |
| 2023 | -7.89% 957/2656 |
3.88% 1103/2280 |
-2.85% 689/2385 |
-2.78% 749/2515 |
-6.12% 1631/2655 |
| 2022 | -17.84% 634/2207 |
-12.30% 599/1919 |
8.31% 373/2016 |
-14.81% 1153/2113 |
1.54% 1232/2208 |
| 2021 | -4.28% 947/1822 |
-4.40% 860/1255 |
5.41% 811/1330 |
-4.43% 707/1466 |
-0.61% 1253/1822 |
| 2020 | 42.50% 266/1250 |
-7.44% 545/1028 |
16.13% 455/1067 |
16.89% 126/1164 |
13.42% 362/1184 |
| 2019 | 40.63% 249/1092 |
27.75% 336/754 |
0.83% 155/804 |
2.03% 331/850 |
7.01% 507/918 |
| 2018 | -22.25% 234/834 |
- - |
- - |
- - |
-11.91% 380/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商沪深300指数增强A VS. 长安沪深300非周期A(740101) |